Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $42.2 million.

  • UroGen Pharma's Total Current Liabilities rose 2884.37% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 2884.37%. This contributed to the annual value of $45.9 million for FY2024, which is 4721.58% up from last year.
  • UroGen Pharma's Total Current Liabilities amounted to $42.2 million in Q3 2025, which was up 2884.37% from $47.5 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Total Current Liabilities peaked at $47.5 million during Q2 2025, and registered a low of $17.0 million during Q1 2021.
  • In the last 5 years, UroGen Pharma's Total Current Liabilities had a median value of $25.8 million in 2023 and averaged $28.3 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 533.17% in 2022, then soared by 5945.33% in 2025.
  • Over the past 5 years, UroGen Pharma's Total Current Liabilities (Quarter) stood at $22.4 million in 2021, then increased by 6.86% to $23.9 million in 2022, then surged by 30.51% to $31.2 million in 2023, then skyrocketed by 47.22% to $45.9 million in 2024, then decreased by 8.06% to $42.2 million in 2025.
  • Its Total Current Liabilities stands at $42.2 million for Q3 2025, versus $47.5 million for Q2 2025 and $42.0 million for Q1 2025.